Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects (n=40) ≥21 years of age with chronic (≥1 year duration) nonischemic cardiomyopathy (NISCM), New York Heart Association (NYHA) functional class II-III symptoms on stable medical therapy (≥3 months of stable doses of β-blocker, angiotensin inhibitor or receptor blocker, and aldosterone inhibitor \[if appropriate\] therapies) with a documented left ventricular (LV) ejection fraction ≤40% and evidence of LV dilation will be eligible for study participation.~* The diagnosis of a nonischemic etiology for the cardiomyopathy must be supported by coronary angiography, stress echocardiography, or nuclear scintigraphy.~* To allow for a comparison of treatment effect in diabetic versus nondiabetic NISCM, half (n=20) of the subjects enrolled will be diabetic~Exclusion Criteria:~* Subjects with HF that is deemed to be ischemic, congenital, valvular, or infiltrative in etiology, or chemotherapy/toxin-induced will not be eligible for enrollment.~* Other exclusion criteria include the presence of a life-threatening illness with a projected survival ≤6 months;~* recurrent ventricular arrhythmias; end-stage renal failure;~* ongoing infection;~* inability to follow-up;~* collagen vascular disease (lupus, sarcoid);~* enrollment in another investigational study;~* unstable or symptomatic peripheral artery disease;~* prior or active Zn supplementation;~* or ongoing alcohol abuse.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHF patients Given Zinc Acetate (Type: EXPERIMENTAL): Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
- Healthy controls (Type: NO_INTERVENTION): Health controls; no zinc acetate administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).